ArticleTherapeutic advances in endocrinology and metabolism2011
Review of therapeutic advances in diabetic retinopathy.
Article in Therapeutic advances in endocrinology and metabolism, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 23 citations in OpenAlex.
- Intravitreal conbercept for diabetic macular oedema: 2-year results from a randomised controlled trial and open-label extension study.The British journal of ophthalmology · 2022Trial
- EfficientNetB0-Based End-to-End Diagnostic System for Diabetic Retinopathy Grading and Macular Edema Detection.Diabetes, metabolic syndrome and obesity : targets and therapy · 2025Article
- Molecular Features of Classic Retinal Drugs, Retinal Therapeutic Targets and Emerging Treatments.Pharmaceutics · 2021Review
- Fibroblast Growth Factor Type 1 Ameliorates High-Glucose-Induced Oxidative Stress and Neuroinflammation in Retinal Pigment Epithelial Cells and a Streptozotocin-Induced Diabetic Rat Model.International journal of molecular sciences · 2021Article
- Role of Choline in Ocular Diseases.International journal of molecular sciences · 2021Review
- Fangchinoline Ameliorates Diabetic Retinopathy by Inhibiting Receptor for Advanced Glycation End-Products (RAGE)-Nuclear Factor Kappa-Light-Chain-Enhancer of Activated B Cells (NF-κB) Pathway in Streptozotocin (STZ)-Induced Diabetic Rats.Medical science monitor : international medical journal of experimental and clinical research · 2019Article
- Cost-effectiveness of fluocinolone acetonide implant (ILUVIEN®) in UK patients with chronic diabetic macular oedema considered insufficiently responsive to available therapies.BMC health services research · 2019Article
- Elevated cell proliferation and VEGF production by high-glucose conditions in Müller cells involve XIAP.Eye (London, England) · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic retinopathy is a common microvascular complication of prolonged diabetes. It is one of the leading causes of vision loss in working age adults and a significant source of morbidity. To reduce the incidence and severity of diabetic retinopathy, it is important to identify patients at risk and promptly implement intensive glycemic and hypertensive control. To date, there are many interventions that can limit moderate and severe vision loss in people with diabetes, including laser photocoagulation, vitrectomy surgery, and intravitreal pharmacological injections. This review aims to define the different stages of diabetic retinopathy and the important therapeutic advances developed to address the major causes of vision loss in each stage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.